Administration of canagliflozin in a lean woman with type 2 diabetes led to rapid excessive body weight loss, resulting in superior mesenteric artery syndrome and euglycemic ketoacidosis.
Case Report (n=1)
No
Does canagliflozin cause rapid body weight loss leading to superior mesenteric artery syndrome and euglycemic ketoacidosis in lean patients with type 2 diabetes?
SGLT2 inhibitors can cause rapid excessive body weight loss in lean patients with type 2 diabetes, potentially leading to superior mesenteric artery syndrome and euglycemic ketoacidosis.
A 58-year-old women who was diagnosed with type 2 diabetes 20 years earlier had been treated with antidiabetic medicines since she was aged 40 years. After sodium-glucose cotransporter 2 inhibitors administration, her bodyweight rapidly decreased from 40 to 30 kg over a period of 3 weeks. She had abdominal symptoms, including nausea, especially after a meal. On admission, physical examinations and laboratory data showed euglycemic ketoacidosis, dehydration and low insulin secretion levels. Additionally, abdominal contrast computed tomography showed the finding of superior mesenteric artery syndrome. This case urges caution, including rapid excessive bodyweight loss and euglycemic ketoacidosis, on the use of sodium-glucose cotransporter 2 for lean diabetes patients.
Hirai et al. (Wed,) conducted a case report in Type 2 diabetes mellitus (n=1). Canagliflozin was evaluated on Development of superior mesenteric artery syndrome and euglycemic ketoacidosis. Administration of canagliflozin in a lean woman with type 2 diabetes led to rapid excessive body weight loss, resulting in superior mesenteric artery syndrome and euglycemic ketoacidosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: